10:04 AM EST - Protox Therapeutics Inc. : has reported a positive Phase 1 study on its PRX302 drug candidate for benign prostatic hyperplasia, a common condition among aging males. Protox Therapeutics Inc.
shares T.PRX are trading up 3 cents at $0.85.
